Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.795 USD | -0.18% | +9.13% | -13.52% |
Mar. 07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
Financials (USD)
Sales 2024 * | 10.51M | Sales 2025 * | 10.3M | Capitalization | 22.73M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | 2.16 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.21 x |
P/E ratio 2024 * |
-1
x | P/E ratio 2025 * |
-1.47
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.98% |
Latest transcript on Lumos Pharma, Inc.
1 day | -0.71% | ||
1 week | +9.13% | ||
Current month | -2.48% | ||
1 month | -1.43% | ||
3 months | -1.43% | ||
6 months | -31.25% | ||
Current year | -13.52% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.75 | -1.79% | 45 219 |
24-04-23 | 2.8 | +4.48% | 17,131 |
24-04-22 | 2.68 | +3.47% | 4,652 |
24-04-19 | 2.59 | -1.15% | 12,311 |
24-04-18 | 2.62 | +3.97% | 12,387 |
Delayed Quote Nasdaq, April 24, 2024 at 02:23 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.52% | 22.73M | |
+3.94% | 43.43B | |
+47.81% | 41.69B | |
+9.56% | 41.31B | |
-10.92% | 27.14B | |
+8.92% | 25.28B | |
-24.78% | 18.47B | |
+29.96% | 12.59B | |
+0.99% | 12.33B | |
+8.24% | 11.03B |
- Stock Market
- Equities
- LUMO Stock